Skip to main
REPL

REPL Stock Forecast & Price Target

REPL Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Replimune Group Inc. has raised the probability of approval for its RP1 + Opdivo combination therapy in anti-PD-1 failed melanoma patients to 85%, indicating significant positive momentum based on recent clinical trial results. The company has secured an improved financial runway into early 2027, bolstered by a strategic amendment to its Hercules Capital loan, which includes $35M in immediate funding and the potential for an additional $120M upon achieving post-approval milestones. Additionally, the RP1 + Opdivo therapy has demonstrated robust efficacy, with an overall response rate increase from 11.5% to 29.8% when compared to prior anti-PD-1 treatments, alongside a favorable safety profile characterized by low rates of severe treatment-related adverse events.

Bears say

Replimune Group Inc. presents a concerning financial outlook, reporting a significant net loss of $70.9 million for FY3Q26, which, while slightly better than estimates, underscores ongoing financial challenges. Key risks impacting the company's future prospects include the potential inability to demonstrate compelling efficacy and safety data in clinical trials, regulatory approval hurdles for the RP1 product, and the possibility of medium- to long-term shareholder dilution. Despite some optimism regarding the FDA's acceptance of a resubmission for RP1, the overarching risks and negative financial metrics raise caution among potential investors.

REPL has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Replimune Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Replimune Group Inc (REPL) Forecast

Analysts have given REPL a Buy based on their latest research and market trends.

According to 8 analysts, REPL has a Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Replimune Group Inc (REPL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.